The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the effect of subretinal fluid on visual outcomes in neovascular age-related macular degeneration.